Fulltext

Molecular markers in gliomas: impact for the clinician

Hofer, Silvia ; Lassman, Andrew

In: Targeted Oncology, 2010, vol. 5, no. 3, p. 201-210

Ajouter à la liste personnelle
    Titre
    • Molecular markers in gliomas: impact for the clinician
    Auteur
    • Hofer, Silvia. Department of Oncology, University Hospital Zürich, Zürich, Switzerland
    • Lassman, Andrew. Department of Neurology and Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:319742
    Summary
    Over the last decade, understanding of glioma on a molecular level has greatly expanded. However, optimal incorporation of molecular markers into clinical care is controversial. We briefly review the potential utility of molecular stratification in refining histologic diagnosis, prognosis, and treatment decisions, focussing on 1p/19q co-deletion, MGMT promoter methylation, EGFR mutations, and IDH mutation. The most recently discovered IDH mutation is a striking example of a rapid implementation of a molecular marker for prognostication into common clinical use